Page last updated: 2024-08-05 11:32:29
3alpha-hydroxy steroid
A 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
ChEBI ID: 36835
Members (24)
| Member | Definition | Role |
|---|---|---|
| 3 alpha,17 alpha-dihydroxy-5 beta-pregnan-20-one | A 17alpha-hydroxy steroid that is 3alpha-hydroxy-5beta-pregnan-20-one carrying an additional hydroxy group at position 17alpha. | 3alpha,17alpha-dihydroxy-5beta-pregnan-20-one |
| 3,7,12-trihydroxycholestan-26-oic acid | A steroid acid that is 5beta-cholestan-26-oic acid which is substituted by hydroxy groups as the 3alpha, 7alpha, and 12alpha positions. | 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-oic acid |
| 3,7,12-trihydroxycoprostane | 5beta-cholestane-3alpha,7alpha,12alpha-triol | |
| 3,7,12-trihydroxycoprostanic acid | 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestane-5-carboxylic acid | |
| 3,7,12,24-tetrahydroxycholestanoic acid | 3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oic acid | |
| 3alpha-hydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | A steroid acid that is ergosta-8,24(28)-dien-26-oic acid substituted by a hydroxy group at position 3, a methyl group at position 4 and oxo groups at positions 7 and 11 (the 3alpha,4alpha,5alpha stereoisomer). Isolated from Antrodia cinnamomea and Antrodia camphorata, it exhibits cytotoxic, anticholinergic and antiserotonergic activities. | zhankuic acid B |
| 3alpha,12alpha-dihydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | A steroid acid that is ergosta-8,24(28)-dien-26-oic acid substituted by hydroxy groups at positions 3 and 12, a methyl group at position 4 and oxo groups at positions 7 and 11 (the 3alpha,4alpha,5alpha,12alpha stereoisomer). Isolated from Antrodia cinnamomea and Antrodia camphorata, it exhibits antineoplastic activity. | zhankuic acid C |
| 7-ketolithocholic acid | A bile acid that is lithocholic acid carrying an additional oxo substituent at position 7. | 7-oxolithocholic acid |
| allocholic acid | An allo-bile acid that is 5alpha-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12. | allocholic acid |
| androsterone | An androstanoid that is 5alpha-androstane having a hydroxy substituent at the 3alpha-position and an oxo group at the 17-position. It is a metabolite of dehydroepiandrosterone . | androsterone |
| brassinolide | brassinolide | |
| castasterone | castasterone | |
| cholestane-3,7,12,26-tetrol | 5beta-cholestane-3alpha,7alpha,12alpha,26-tetrol | |
| cholic acid | A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12. | cholic acid |
| dihydroxycoprostane | 5beta-cholestane-3alpha,7alpha-diol | |
| etiocholanolone | An androstanoid that is 5beta-androstane substituted by an alpha-hydroxy group at position 3 and an oxo group at position 17. It is a metabolite of testosterone in mammals. | 3alpha-hydroxy-5beta-androstan-17-one |
| fusidic acid | A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum. | fusidic acid |
| muricholic acid | A group of trihydroxy-5beta-cholanic acids that are the 6,7-diastereoisomers of 3alpha,6,7-trihydroxy-5beta-cholan-24-oic acid. | muricholic acids |
| obeticholic acid | A dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatment of primary biliary cholangitis. | obeticholic acid |
| pregnanolone | The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one. | 3alpha-hydroxy-5beta-pregnan-20-one |
| rocuronium | A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents. | rocuronium |
| scymnol | 5beta-scymnol | |
| tetrahydrocortisol | tetrahydrocortisol | |
| ursocholic acid | A bile acid that is 5beta-cholan-24-oic acid bearing three hydroxy substituents at positions 3alpha, 7beta and 12alpha. | ursocholic acid |
Research
Studies (11,308)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3,351 (29.63) | 18.7374 |
| 1990's | 1,700 (15.03) | 18.2507 |
| 2000's | 2,399 (21.22) | 29.6817 |
| 2010's | 2,887 (25.53) | 24.3611 |
| 2020's | 971 (8.59) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 1,171 (9.16%) | 5.53% |
| Reviews | 722 (5.65%) | 6.00% |
| Case Studies | 706 (5.52%) | 4.05% |
| Observational | 72 (0.56%) | 0.25% |
| Other | 10,114 (79.11%) | 84.16% |